What these compounds actually are
One page per compound: what it is, how it is thought to work, what the evidence genuinely shows, whether any regulator has approved it, and what the risks are. Where a compound is an approved medicine, that is stated. Where there is no human evidence at all, that is stated too.
How to read these pages
Most of what gets discussed in peptide circles has never been tested in a person. That does not make it useless, but it does mean the honest answer to "what dose should I take" is usually "nobody has established one". These pages say so rather than filling the gap with a number from a forum.
The one the EDS community asks about most. Animal data on tendon and gut healing is genuinely interesting; human data barely exists.
Tissue Repair TB-500A fragment of a protein your body already makes. Human trials exist, which is unusual here, but they were for eyes and wounds rather than joints.
Tissue Repair GHK-CuStrong evidence as a skin ingredient you put on. Much weaker evidence as something you inject.
Tissue Repair KLOW blendFour compounds in one vial. Each has its own thin evidence base, and the combination has none at all.
Tissue Repair GLOW blendKLOW without the KPV. Same situation: no studies of the combination.
Tissue Repair Wolverine blendThe two repair peptides together. Popular in injury contexts; the pairing itself is untested.
Growth Hormone Axis IpamorelinMade it into real human trials, then was dropped. Selective, short-acting, and genuinely studied — just not approved.
Growth Hormone Axis CJC-1295A growth hormone releasing hormone analogue. The 'with DAC' version lasts days rather than minutes.
Growth Hormone Axis TesamorelinOne of the few here that is an actual approved medicine — for a specific condition that is not hypermobility.
Incretin / GLP-1 PLP-1 SThe compound behind Ozempic and Wegovy. Approved, extensively studied, and with a side-effect profile that matters a lot if you have EDS.
Incretin / GLP-1 PLP-2 TDual GIP and GLP-1. Approved as Mounjaro and Zepbound. Same gastric emptying caution as semaglutide, and then some.
Incretin / GLP-1 PLP-3 RTriple agonist, still in Phase 3, not approved anywhere. The Phase 2 results were striking, which is exactly why caution matters.
Metabolic MOTS-cA peptide your mitochondria encode themselves. Interesting biology, almost entirely animal evidence.
Neuro & Sleep DSIPNamed for an effect that later research struggled to reproduce consistently.
Neuro & Sleep SemaxApproved in Russia, nowhere else. Most of the literature is in Russian and hard to appraise from outside.
Metabolic GlutathioneA real and important antioxidant. Whether injecting it does more than eating well is the open question.
Metabolic NAD+Not a peptide. A coenzyme central to energy metabolism, sold widely on the back of ageing research.
Reproductive & Hormonal PT-141Another genuinely approved one, for a narrow indication.
Reproductive & Hormonal Melanotan IIThe one with the clearest documented harms. Worth reading the risks before anything else.
Immune Thymosin alpha-1Approved in a number of countries, though not the US. Mainly an immune modulator.
The rest of the catalog, in brief
These have the same answer as most of the library — little or no human evidence — so they get a line each rather than a page that repeats itself.
| Sermorelin | GHRH analogue. Was approved in the US as Geref and later withdrawn from the market for commercial reasons. |
|---|---|
| GHRP-6 | Older growth hormone secretagogue. Strongly stimulates appetite. Not approved. |
| Hexarelin | Potent GH secretagogue; tolerance develops quickly. Not approved. |
| IGF-1 LR3 | Long-acting IGF-1 analogue. Not approved; significant hypoglycaemia risk. |
| IGF-DES | IGF-1 variant. Not approved. Same hypoglycaemia concern. |
| ACE-031 | Myostatin pathway inhibitor. Human trials were halted over bleeding and vascular side effects. |
| GDF-8 | Myostatin itself. Research reagent, not a therapeutic. |
| Cagrilintide | Amylin analogue, investigational, studied in combination with semaglutide. |
| Survodutide | GLP-1 and glucagon dual agonist. Investigational, Phase 3. |
| Mazdutide | GLP-1 and glucagon dual agonist. Investigational in the US. |
| AOD9604 | Growth hormone fragment. Failed to beat placebo for weight loss in human trials. |
| 5-Amino-1MQ | NNMT inhibitor. Preclinical only. |
| SLU-PP-332 | ERR agonist, exercise-mimetic research compound. Preclinical only. |
| AICAR | AMPK activator. Research compound; prohibited in sport. |
| SS-31 | Also called elamipretide. Mitochondria-targeted; has been through human trials in rare mitochondrial disease. |
| Epitalon | Tetrapeptide with telomerase claims resting on limited Russian-language work. |
| Pinealon | Short peptide from the same Russian bioregulator tradition. Minimal independent evidence. |
| Selank | Anxiolytic peptide registered in Russia. Not approved elsewhere. |
| FOXO4-DRI | Senolytic research peptide. Mouse data only. |
| Thymalin | Thymic extract from the Russian bioregulator literature. |
| LL-37 | Human antimicrobial peptide. Research use; pro-inflammatory effects are dose-dependent. |
| ARA-290 | Erythropoietin-derived peptide studied in small trials for sarcoidosis-related neuropathy. |
| VIP | Vasoactive intestinal peptide. Investigational. |
| PNC-27 | Anti-cancer research peptide. Cell-culture evidence only; no human trials. |
| KPV | Alpha-MSH fragment with anti-inflammatory activity in animal colitis models. |
| Kisspeptin | Regulates GnRH release. Used as a research probe of reproductive physiology. |
| HCG | An approved medicine with established fertility and endocrine indications. |
| HMG | Approved gonadotropin preparation used in fertility treatment. |
| Snap-8 | Cosmetic peptide used topically in skincare. |
| B12 | Cyanocobalamin. An established vitamin preparation, not a research peptide. |